Follow The Leader: The cost of listening to only 1 guideline

Written By Ian Riddock
Medical Disclaimer: This article is for educational purposes only and should not replace professional medical advice. Always consult with a qualified healthcare provider regarding diagnosis, treatment options, and personal health decisions. If you experience chest pain, shortness of breath, or other emergency symptoms, seek immediate medical attention.

Case Presentation

Setting: American College of Cardiology (ACC) 62nd Annual Scientific Session, San Francisco, CA | March 9-11, 2013

A packed crowd, spilling out into the foyer of the lecture hall, awaited the much anticipated release of the new 2013 ACC/AHA Blood Cholesterol Guidelines. They weren't quite ready and they were not released at that time, so a Q&A session with the Guideline writing committee members was held instead, offering a hint of what we might expect from these guidelines.

Based on what they had already heard, an audience participant asked one of the Guideline writers what they would do in the following situation:

The Scenario: A patient who had had an ASCVD event who was placed on a maximum high intensity statin, like Atorvastatin 80 mg daily, but achieved an on-treatment LDL-C of just over 100 mg/dL (previous guidelines called for LDL < 70 mg/dL). What next?

Guideline writer's reply: "I think you're done."

This was a stark departure from prior and existing guidelines and in this particular scenario, offered a treatment strategy that was inferior to the current standard of care, leaving countless high risk patients at risk for undertreatment and exposing them unnecessarily to excess residual risk.

It seemed to promote the outdated "fire and forget" strategy (enjoyed by the lazy practitioner), where all you needed to do was place your high risk patients on a "high intensity statin" and call it a day. "Poof", done. Never check a lipid panel again. Obviously, that's not exactly what was said, nor intended by the Guideline Committee, but that's how it was received by many.

Flying Under the Radar

"But my doctor is following the guidelines - is it possible that I am being undertreated?" Yes, it is. Providers are human and they often "follow the leader." When it comes to cardiovascular guidelines, the leader is often the American College of Cardiology and the American Heart Association (ACC/AHA).

However guidelines are just that - guidelines. They don't always apply to everyone (for instance, certain ethnic groups). They don't always apply to every situation. There are many of them out there and they're not always created equal. And yes, as well respected as these organizations are, sometimes they get it wrong. That was the case with the 2013 ACC/AHA Blood Cholesterol Guidelines. They were well intentioned and they had their reasons, but it was a swing and a miss and set the lipid community back several years.

Fortunately, medicine is a team sport. Other stakeholders picked up the baton, ran with it and tried to make up for lost ground.

CardioAdvocate Checklist

For Patients and Providers

Know Your Baseline Risk
Identify your risk category:
  • Highest Risk — Secondary prevention: >20% ten year risk of ASCVD event, CAC >300, Familial Hypercholesterolemia, Elevated Lp(a) >325 nmol/L, High lifetime risk
  • Use multiple risk calculators including ACC/AHA PCE, Reynolds (includes family history and hs CRP), Framingham, and European HeartScore
Consider multiple guidelines — Choose the guideline(s) most applicable to the individual being treated
Consider Expert Opinion within the framework of a patient-centered discussion with your care team members. If in doubt, seek expert advice from a cardiometabolic specialist or lipidologist

Recommended Resources

Expert Thought Leaders

Deep Dive

The 2013 ACC/AHA Blood Cholesterol Guidelines: An Interesting Story

The 2013 ACC/AHA Blood Cholesterol Guidelines were created under the strictest interpretation of "Evidence Based Medicine," allowing only for data obtained from Randomized Controlled Trials (RCT) and/or meta-analysis of Randomized Controlled Trials in crafting recommendations. This painted them into a corner and effectively created a situation where they undermined existing guidelines and were forced to abandon any sort of lipid goal or target. Instead, they vehemently declared that clinical trials to date had only shown that a particular dose of statin had achieved the positive outcomes, rather than a particular LDL-C goal attained, for instance.

Historical Context: The Path to 2013

Since 1985 the National Cholesterol Education Program has been managed by the NHLBI, a division of the NIH and produced guidelines on cholesterol. The last guideline published was the Adult Treatment Panel III (NCEP ATPIII) in 2001 and updated in 2004 (ATP III Report on High Blood Cholesterol) to include an optional goal of LDL-C < 70 mg/dL for very high risk patients. Its 284 pages is a tour de force in how to write a guideline. It was chaired by Scott Grundy M.D., Ph.D., a legend in the field of atherosclerosis. The guideline reviewed and appropriately weighted the totality of available scientific evidence, providing useful and balanced recommendations. Within its text is an abundance of educational material to include the criteria for metabolic syndrome. It remains a great resource for anyone interested in understanding atherosclerosis.

The next iteration of guidelines were nearly complete, when in 2013 the NHLBI decided to no longer participate in the publication of various cardiometabolic guidelines to include cholesterol, high blood pressure, obesity and nutrition, turning these duties over to various stakeholders such as the ACC/AHA for the cholesterol guidelines. The guidelines writers remained intact. In trying to adhere to the Institute of Medicine's "guidelines for writing evidence-based guidelines," which prioritized RCTs above all other sources of evidence, it decided to completely restrict the 2013 Blood Cholesterol Guidelines from anything but RCT data, rather than simply prioritizing it.

The Irony: The ACC/AHA's risk calculator, the so-called Pooled Cohort Equation (ASCVD Risk Estimator +), which was derived from and promoted by the guidelines, had never been evaluated in any sort of RCT.

Populations and Disparities: What About Other Ethnic Groups?

Many ethnic groups have published lipid guidelines or consensus statements more applicable to their risk, such as:

The Challenge of Standardization: Lipid Goals by Risk Categories

Unfortunately, as is often the case in medicine when multiple stakeholders are involved, there is no standardization of nomenclature when it comes to defining and categorizing risk. We have attempted to break down some of the more popular guidelines and statements with their respective risk categories, definitions and related lipid goals and recommendations.

AACE/ACE Risk Categories

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary

Extreme Risk

Risk Factors:

  • Progressive ASCVD including unstable angina
  • Established clinical ASCVD + diabetes or CKD ≥3 or HeFH
  • History of premature ASCVD (<55y Male, <65y Female)

Treatment Goals:

  • LDL-C <55 mg/dL "and" ≥50% reduction from baseline
  • Non-HDL-C <70 mg/dL
  • ApoB <70 mg/dL
  • TG <150 mg/dL
Important: For example, if your LDL-C is 72 mg/dL at baseline, the goal would be <36 mg/dL! It is not 54 mg/dL. Far too many clinicians mistakenly practice this way. It is more of a threshold to treat with high intensity (>50% reduction of LDL-C). That's a huge difference!

Very High Risk

Risk Factors:

  • Established clinical ASCVD or recent hospitalization for ACS, carotid or peripheral vascular disease, or 10 y risk >20%
  • Diabetes w/ ≥1 risk factor
  • CKD ≥3 w/ albuminuria
  • HeFH

Treatment Goals:

  • LDL-C <70 mg/dL "and" ≥50% reduction from baseline
  • Non-HDL-C <100 mg/dL
  • ApoB <80 mg/dL
  • TG <150 mg/dL

High Risk

Risk Factors:

  • ≥2 risk factors & 10 y risk >10-20%
  • Diabetes or CKD ≥3 & no other risk factors
  • ≥3 & no other risk factors

Treatment Goals:

  • LDL-C <70 mg/dL "and" ≥50% reduction from baseline
  • Non-HDL-C <100 mg/dL
  • ApoB <80 mg/dL
  • TG <150 mg/dL

Moderate Risk

Risk Factors:

  • <2 risk factors & 10 y risk <10%

Treatment Goals:

  • LDL-C <100 mg/dL
  • Non-HDL-C <130 mg/dL
  • ApoB <90 mg/dL
  • TG <150 mg/dL

Low Risk

Risk Factors:

  • No risk factors

Treatment Goals:

  • LDL-C <130 mg/dL
  • Non-HDL-C <160 mg/dL
  • ApoB - not recommended
  • TG <150 mg/dL

ESC/EAS Risk Categories

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Very High Risk

Risk Factors:

  • Recurrent ASCVD events (more than 1)
  • Extensive atherosclerotic cardiovascular disease
  • Higher global cardiovascular risk scores

Lipid Goals (Primary or Secondary Prevention):

  • LDL-C <55 mg/dL "and" ≥50% reduction from "baseline"
  • LDL-C <40 mg/dL — Patients with ASCVD with another vascular event within 2 years (not necessarily the same type of event)
  • Non-HDL-C <85 mg/dL
  • Apolipoprotein B (ApoB) <65 mg/dL
Note on LDL-lowering: ESC/EAS says "LDL-lowering therapy," not necessarily "statin" therapy. The benefits derived from "high intensity statin" are dependent on the achieved LDL-C levels in individual trial participants. Notice they also say "LDL-lowering," not necessarily "LDL-C" — ApoB and LDL-P are other acceptable biomarkers.

High Risk

Risk Factors:

  • Markedly elevated single risk factor (LDL-C ≥190 mg/dL - severe hypercholesterolemia including FH; BP ≥180/110 mmHg)
  • Familial Hypercholesterolemia (FH) without any additional risk factors
  • Moderate CKD (Stage 3: eGFR 30-59 mL/min/1.73 m²)
  • DM without target damage
  • DM ≥10 years or with another risk factor
  • European HeartScore ≥5% and <10% 10 year risk of fatal CVD

Lipid Goals:

  • LDL-C <70 mg/dL "and" ≥50% reduction from "baseline"
  • Non-HDL-C <100 mg/dL
  • ApoB <80 mg/dL

Moderate Risk

Risk Factors:

  • Young patients (T1DM <35 years, T2DM <50 years) with DM <10 years, without other risk factors
  • European HeartScore ≥1% and <5% 10 year risk of fatal CVD

Lipid Goals:

  • LDL-C <100 mg/dL

Low Risk

Risk Factors:

  • European HeartScore <1% 10 year risk of fatal CVD

Lipid Goals:

  • LDL-C <116 mg/dL

All Patients

Consider:

  • Lipoprotein a (Lp(a)): Considered at least once in every adult's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (430 nmol/L). Considered in those with family history of premature CVD. Considered for reclassification of risk in borderline cases.
  • Triglycerides: TG <150 mg/dL indicates lower risk; TG >150 mg/dL, look for other risk factors
  • Diabetes: A1C <7%

2014 National Lipid Association Management of Dyslipidemia Guidelines

Very High Risk

Risk Factors:

  • ASCVD
  • DM - Type 1 or 2 with ≥2 other major ASCVD risk factors or end organ damage (microalbuminuria ≥30 mg/g, CKD, retinopathy)

Lipid Goals:

  • LDL-C <70 mg/dL and >50% reduction from baseline
  • Non-HDL <100 mg/dL
  • ApoB <80 mg/dL

High Risk

Risk Factors:

  • LDL-C ≥190 mg/dL - severe hypercholesterolemia, including FH
  • CKD ≥Stage 3B
  • DM with 0-1 other major ASCVD risk factors

Lipid Goals (High, Moderate, Low Risk - Primary Prevention):

  • LDL-C <100 mg/dL
  • Non-HDL <130 mg/dL
  • ApoB <90 mg/dL

2018 AHA/ACC Guidelines

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

The AHA/ACC Cholesterol guidelines are best summed up with their recommendations regarding secondary prevention (ASCVD) and primary prevention. These guidelines represent a more conservative approach compared to the ESC/EAS recommendations.

Expert Opinion: Advanced Atherosclerosis

Beyond published guidelines, expert consensus statements offer additional insight:

Advanced atherosclerosis:

  • LDL-C range between 20-40 mg/dL
  • Based upon PCSK9i trials: FOURIER, ODYSSEY, GLAGOV
  • Expert Opinion White Paper: "There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision"
  • A patient centered discussion may be had to discuss safety, efficacy and cost ratios

Other Notable Guidelines

So Which Guidelines Do I Follow?

In our opinion, that is up to the joint decision making of the patient and their care team.

There are numerous Cholesterol guidelines published by various organizations and medical societies around the globe. Some are more conservative than others. Some are more popular than others and get more attention. That doesn't always mean they are the most applicable to each unique patient with their own unique characteristics and circumstances.

Our mission at CardioAdvocate.com is to eradicate atherosclerotic cardiovascular disease in everyone. We wish to make published resources and expert recommendations more available, thereby facilitating a more informed personalized discussion.

In our highest risk patients, such as The Repeat Offender (The Heart Attack Survivor) we tend to align ourselves with the more aggressive lipid lowering recommendations, to include expert consensus opinion, rather than the more conservative recommendations of others, despite their popularity.

We agree with the following statement when it comes to our highest risk patients:

"LDL-C levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients" - 2019 Joint ESC/EAS Dyslipidemia Guidelines

Put another way by Dr. John Kastelein at the ESC meeting in 2019: "LDL-C is a toxic agent that in principle needs eradication, but in practice needs early, long-term and aggressive lowering"

Conservative vs. Aggressive Approaches

By way of comparison, the more conservative 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol calls for a more conservative LDL-C threshold of 70 mg/dL for the addition of non-statins to maximally tolerated statins. It also calls for multiple major ASCVD events to occur or to have had a major ACVD event combined with multiple risk factors before the most aggressive action is taken.

In our view: Simply having any major ASCVD event is plenty and requires the most aggressive and urgent action ASAP!

2025 ESC/EAS Focused Update — Breaking the Sisyphean Cycle?

In January 2026, Kausik Ray and Florian Kronenberg published a commentary in Atherosclerosis titled "Seventeen Years to Change Practice." The title alone says everything. Despite decades of evidence, it takes on average 17 years for medical guidelines to reach routine clinical care. The 2025 ESC/EAS Focused Update on dyslipidaemia management aims to break this cycle.

Key Shifts in the 2025 ESC/EAS Focused Update:

  • Risk Assessment Modernized: SCORE2 and SCORE2-OP now factor in both fatal and non-fatal events and extend risk prediction up to age 89. Critically, this corrects years of underestimating risk in women and younger individuals.
  • Expanded Lipid-Lowering Toolbox: New therapies include bempedoic acid, evinacumab, inclisiran, and high-dose icosapent ethyl — specifically not EPA+DHA mixtures.
  • ACS Management Shift: The outdated "stepwise" escalation approach is replaced by immediate high-intensity statin plus ezetimibe for most patients post-ACS.
  • Lp(a) Testing Standardized: Universal Lp(a) testing recommended at least once in adulthood, optimally with the first lipid profile. Lp(a) is positioned as a continuous, risk-enhancing factor.
  • New Extreme Risk Category: Patients with recurrent ASCVD events despite intensive therapy now have dedicated recognition and treatment guidance.

The Implementation Gap: JACC Stats 2026

Following the release of the 2025 ESC/EAS Focused Update, the inaugural JACC Cardiovascular Statistics 2026 (Wadhera et al.) report delivered a sobering reality check. Despite therapeutic advances — PCSK9 inhibitors, inclisiran, bempedoic acid, ezetimibe — population-level cardiovascular health has stalled or reversed:

  • LDL-C targets: Most high-risk patients still fail to reach guideline-recommended LDL-C goals
  • Statins underused: Even among patients with established ASCVD, statin prescribing and adherence remain suboptimal
  • Young adult MI rising: After years of decline (2004–2010), MI hospitalizations in young adults are increasing again — driven by obesity, diabetes, and metabolic syndrome
  • Obesity epidemic: Now affects >40% of U.S. adults, up from 34.5% in 2011–2012
Long-Acting Lipid Therapies — A Game-Changer? At a recent UTHealth Houston symposium, experts outlined how twice-yearly injectable medications could fundamentally reshape lipid management. Long-acting PCSK9 inhibitors and siRNA-based therapies (like inclisiran) reduce LDL-C with just 1–2 injections per year, removing the daily adherence burden that undermines statin therapy. If these agents reach scale, lifetime cholesterol burden — and with it, lifetime ASCVD risk — could be dramatically reduced.

Questions to Ask Your Care Team

  • Has my Lp(a) ever been checked? The new guidelines recommend testing at least once in every adult's lifetime.
  • I'm a woman with borderline risk — are newer risk calculators being used that better account for my risk?
  • I had a heart attack — should I be on combination therapy now rather than waiting to see if statins alone work?

The Bottom Line

Guidelines keep improving. But as Ray and Kronenberg point out, without a fundamental change in how we implement evidence, we risk repeating the Sisyphean cycle — rolling the boulder up the hill only to watch it roll back down. CardioAdvocate exists to help close that gap.

The 2013 ACC/AHA guidelines represented a well-intentioned but ultimately flawed interpretation of what "evidence-based medicine" should be. By restricting themselves to RCT data alone, guideline writers inadvertently created a situation where patients were potentially undertreated.

Fortunately, the broader medical community — including ESC/EAS, AACE/ACE, NLA, and other stakeholders — continued to provide more aggressive recommendations grounded in clinical expertise and a broader interpretation of the evidence base.

The path forward requires:

  • Patient-centered care informed by multiple guidelines
  • Recognition that guidelines are starting points, not endpoints
  • Access to specialist input when patients fall outside standard categories
  • Regular monitoring and reassessment of lipid levels
  • Aggressive treatment of highest-risk patients, not complacency

Don't accept undertreatment simply because you're "following the guidelines." Ask your care team which guidelines they're using, why they chose those guidelines, and whether your individual circumstances warrant a more aggressive approach. The guidelines are there to guide you — not to limit you.

February 2026 Update: The inaugural JACC Cardiovascular Statistics 2026 (Wadhera et al., PubMed) report confirms the implementation gap remains the real crisis — most high-risk patients still fail to reach LDL-C targets, statins remain underused, and young adult MI hospitalizations are rising. Meanwhile, innovation continues: twice-yearly injectable lipid-lowering therapies (including long-acting PCSK9 inhibitors and siRNA agents like inclisiran) could dramatically reduce lifetime cholesterol burden and solve the adherence problem that undermines even the best guidelines. The question is no longer whether we have the tools — it's whether we use them.

CardioAdvocate helps people understand what matters — and how to speak up about it.

Foot Stompers: Key Takeaways

🦶 Foot Stomper
Guidelines lag behind science: By the time a guideline committee convenes, debates, and publishes, the evidence has often moved on; the best clinicians treat to the latest evidence, not just the latest guideline.
🦶 Foot Stomper
LDL-C below 55 mg/dL for secondary prevention: The European ESC guideline already says this; U.S. guidelines haven't caught up yet, but the evidence is overwhelming.
🦶 Foot Stomper
ApoB is the better metric: Every major guideline society now acknowledges ApoB's superiority to LDL-C alone, yet most doctors still don't order it; ask for yours.
🦶 Foot Stomper
Therapeutic inertia kills: Studies show the majority of high-risk patients never reach their lipid targets; it's not that we lack the drugs, it's that we fail to intensify therapy.

Reference

Ray KK, Kronenberg F. "Seventeen Years to Change Practice: Will the 2025 ESC/EAS Dyslipidaemia Guidelines Finally Break the Sisyphean Cycle?" Atherosclerosis 2026;120636.

Recommended Resources

Guidelines and Position Statements

Risk Assessment Tools

Specialist Resources

Related CardioAdvocate Content

Disclaimer: This article is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare providers with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking treatment because of information in this article. CardioAdvocate.com does not endorse any specific treatment, medication, or procedure mentioned herein. Readers are responsible for independently verifying all information and consulting with appropriate healthcare professionals before making any medical decisions.
Ian Riddock
Previous

The “Incidentaloma”: Coronary Artery Disease “Hiding” in Your Medical Records
Next

Something Smells Fishy: The Benefits and Controversies of Fish Oil and Icosapent Ethyl